Le Registre des lobbyistes
| Objets | Détails | Catégories |
|---|---|---|
|
Recherche et développement, Sciences et technologies
|
Government policies regarding innovation, research and development, and messenger ribonucleic acid (mRNA) biotechnology
|
Politique ou Programme
|
|
Marchés publics, Santé
|
Health Canada and Public Services and Procurement Canada policies regarding the development, procurement, and distribution of Moderna’s COVID-19 vaccine to various segments of the population, including future distribution models
|
Politique ou Programme
|
|
Développement économique, Santé
|
The government’s Pandemic Preparedness Strategy as it relates to the corporation’s future operations in Canada
|
Politique ou Programme
|
Moderna is a biotech company focusing on vaccine technologies. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.
Stefan Raos, General Manager, Canada
Date de la fin du dernier exercice financier complet : 2024-12-31
| Institution gouvernementale | Financement reçu au cours du dernier exercice financier | Financement attendu pendant l'exercice financier en cours |
|---|---|---|
| Investissement Quebec | 18 637 142,00 $ | Oui |
| Ministry of Economic Development, Job Creation and Trade | 0,00 $ | Oui |
Adresse :
155 Wellington St W
Suite 3130
Toronto, ON M5V 3H1
Canada
Numéro de téléphone :
647-503-0703